This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ludwig, A. T. Articles by Griffith, T. S. Search for Related Content PubMed PubMed Citation Articles by Ludwig, A. T. Articles by Griffith, T. S.

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand

A Novel Mechanism for Bacillus Calmette-Guérin-Induced Antitumor Activity

Department of Urology, University of Iowa, Iowa City, Iowa

Mycobacterium bovis Bacillus Calmette-Guérin (BCG) use in the treatment of bladder cancer was first reported in 1976, but the mechanism of the induced antitumor activity has still not been fully explained. BCG is a potent immunostimulant, normally producing a Th1 cytokine response, including IFN. Recent studies have shown CpG oligodeoxynucleotide induce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression via IFN production. Given that Mycobacterial DNA contains high amounts of CpG motifs, we hypothesized that BCG’s antitumor properties are akin to CpG oligodeoxynucleotide, where the cytokine response to BCG induces TRAIL up-regulation. Using ELISA, urine IFN-, and TRAIL levels were initially undetectable in BCG therapy patients but were high after later induction treatments. More importantly, patients that responded to BCG therapy had significantly higher urine TRAIL levels, which killed bladder tumor cells in vitro versus nonresponders. Flow cytometry of fresh urine revealed TRAIL-expressing neutrophils. Given these data, we propose TRAIL plays a role in BCG-induced antitumor effects.

This article has been cited by other articles:

				A. M. Kamat, S. T. Tharakan, B. Sung, and B. B. Aggarwal Curcumin Potentiates the Antitumor Effects of Bacillus Calmette-Guerin against Bladder Cancer through the Downregulation of NF-{kappa}B and Upregulation of TRAIL Receptors Cancer Res., December 1, 2009; 69(23): 8958 - 8966. [Abstract] [Full Text] [PDF]

				M. P. Simons, K. G. Leidal, W. M. Nauseef, and T. S. Griffith TNF-related apoptosis-inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules J. Leukoc. Biol., March 1, 2008; 83(3): 621 - 629. [Abstract] [Full Text] [PDF]

				T. Yoshida, T. Maoka, S. K. Das, K. Kanazawa, M. Horinaka, M. Wakada, Y. Satomi, H. Nishino, and T. Sakai Halocynthiaxanthin and Peridinin Sensitize Colon Cancer Cell Lines to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Mol. Cancer Res., June 1, 2007; 5(6): 615 - 625. [Abstract] [Full Text] [PDF]

				M. P. Simons, J. M. Moore, T. J. Kemp, and T. S. Griffith Identification of the Mycobacterial Subcomponents Involved in the Release of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand from Human Neutrophils Infect. Immun., March 1, 2007; 75(3): 1265 - 1271. [Abstract] [Full Text] [PDF]

				A. Papageorgiou, A. Kamat, W. F. Benedict, C. Dinney, and D. J. McConkey Combination therapy with IFN-{alpha} plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells Mol. Cancer Ther., December 1, 2006; 5(12): 3032 - 3041. [Abstract] [Full Text] [PDF]

				M. A. Cassatella On the production of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) by human neutrophils J. Leukoc. Biol., June 1, 2006; 79(6): 1140 - 1149. [Abstract] [Full Text] [PDF]

				J. K. Earel Jr., R. L. VanOosten, and T. S. Griffith Histone Deacetylase Inhibitors Modulate the Sensitivity of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Resistant Bladder Tumor Cells Cancer Res., January 1, 2006; 66(1): 499 - 507. [Abstract] [Full Text] [PDF]

				M. A. Cassatella, V. Huber, F. Calzetti, D. Margotto, N. Tamassia, G. Peri, A. Mantovani, L. Rivoltini, and C. Tecchio Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators J. Leukoc. Biol., January 1, 2006; 79(1): 123 - 132. [Abstract] [Full Text] [PDF]

				T. J. Kemp, A. T. Ludwig, J. K. Earel, J. M. Moore, R. L. VanOosten, B. Moses, K. Leidal, W. M. Nauseef, and T. S. Griffith Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L Blood, November 15, 2005; 106(10): 3474 - 3482. [Abstract] [Full Text] [PDF]

				N. Zerafa, J. A. Westwood, E. Cretney, S. Mitchell, P. Waring, M. Iezzi, and M. J. Smyth Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies J. Immunol., November 1, 2005; 175(9): 5586 - 5590. [Abstract] [Full Text] [PDF]

				A. Papageorgiou, L. Lashinger, R. Millikan, H. B. Grossman, W. Benedict, C. P. N. Dinney, and D. J. McConkey Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Interferon-Induced Apoptosis in Human Bladder Cancer Cells Cancer Res., December 15, 2004; 64(24): 8973 - 8979. [Abstract] [Full Text] [PDF]